RPT 904
Alternative Names: Anti-immunoglobulin E antibody - Jemincare; JYB-1904; RPT-904Latest Information Update: 29 Oct 2025
At a glance
- Originator Jemincare
- Class Antiasthmatics; Antibodies; Biobetters; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Immunoglobulin E inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Allergic asthma; Chronic urticaria
Most Recent Events
- 20 Oct 2025 Efficacy and adverse events data from a phase II trial in Chronic spontaneous urticaria released by RAPT Therapeutics
- 29 Sep 2025 The US FDA clears an IND application to initiate a phase IIb trial for Food hypersensitivity
- 28 Jun 2025 No recent reports of development identified for phase-I development in Asthma(In volunteers) in China (SC, Injection)